VISEN Pharmaceuticals

TransCon™ PTH PDUFA date of April 30, 2023, for adults with hypoparathyroidism; European MAA decision expected in the fourth quarter of 2023Expanding TransCon hGH geographic reach with planned launch in Germany in the third quarter of 2023; Phase 3 data in adult GHD indication expected in the fourth quarter of 2023 Initiated Phase 2b ApproaCH Trial for TransCon CNP in achondroplasia; expected to complete enrollment in the second quarter of 2023SKYTROFA® U.S. revenue grew to €17.1 million in the fourth quarter of 2022, providing a foundation for growth in 2023 and beyondConference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the full year ended December 31, 2022 and provided a business update. “Our unique TransCon technology platform and algorithm for product innovation enables us to address major unmet medical needs with a diverse, growing pipeline of highly differentiated product candidates,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “With our demonstrated ability to take a product from concept through approval and launch, we will continue to focus on building long term value for patients and other stakeholders, establishing Ascendis Pharma as a leading sustainable, profitable biopharma company.” Select Highlights & Anticipated 2023 Milestones TransCon hGH: First European SKYTROFA (lonapegsomatropin) commercial launch in Germany on track for the third quarter of 2023.In the third quarter of 2023, we anticipate completing enrollment in New InsiGHTS, a four-armed Phase 2 trial designed to investigate the safety, tolerability, and efficacy of different dose levels of TransCon hGH in patients with Turner Syndrome.We expect Phase 3 topline results from foresiGHt in adult growth hormone deficiency in the fourth quarter of 2023.Fourth quarter 2022 SKYTROFA (lonapegsomatropin-tcgd) U.S. revenue grew to €17.1 million. TransCon PTH: U.S. FDA Priority Review continues for use in adult patients with hypoparathyroidism, with a PDUFA date of April 30, 2023. If approved, U.S. commercial launch expected by the end of the second quarter of 2023.European Commission decision on MAA anticipated during the fourth quarter of 2023. If approved, first European country launch expected in early 2024.In anticipation of U.S. and EU approvals, commercial, medical affairs, product supply and other teams continue launch readiness activities.Phase 3 PaTHway Japan trial achieved its primary objectives; topline results consistent with North American and EU trials.Enrollment opened in January 2023 for U.S. Expanded Access Program. Q1-2022Q2-2022Q3-2022Q4-20222022SKYTROFA revenue (millions)€1.9€4.4€12.3€17.1€35.7 TransCon CNP: Announced positive topline data from the Phase 2 ACcomplisH Trial, with results in children with achondroplasia down to 2 years of age; as of February 14, 2023 all 57 patients currently remain in the trial with treatment duration up to 3 years.During the second quarter of 2023, we expect to complete enrollment in ApproaCH, a global randomized, double-blind, placebo-controlled Phase 2b trial in children ages 2–11 years with achondroplasia. The trial targets enrollment of ~80 patients.During the third quarter of 2023, we plan to submit an IND or similar in children under the age of two years with achondroplasia. TransCon TLR7/8 Agonist: Reported topline data and recommended Phase 2 dose from the dose escalation portion of the Phase 1/2 transcendIT-101 Trial. Early signs of clinical activity were observed in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab.Enrollment in the dose expansion phase of transcendIT-101 continues, with a focus on investigating TransCon TLR7/8 Agonist in combination with pembrolizumab in four different cancer types. TransCon IL-2 β/γ: The Phase 1/2 IL-βelieγe Trial evaluating TransCon IL-2 β/γ monotherapy in patients with locally advanced or metastatic solid tumors continues to enroll patients. Results from monotherapy dose escalation are expected during the first quarter of 2023. Dose escalation combination therapy results expected during the third quarter of 2023.Preparing to initiate βelieγe-IT-201, a randomized Phase 2 trial of TransCon IL-2 β/γ and TLR7/8 combination therapies, in the second quarter of 2023. TransCon RBZ: Ophthalmology selected as the third therapeutic area; TransCon RBZ (ranibizumab) selected as the first investigational pipeline candidate, designed for higher efficacy with 6-month dosing intervals. Ended the fourth quarter of 2022 with cash, cash equivalents, and marketable securities totaling €742.9 million. Full-Year 2022 Financial Results Total revenue for 2022 was €51.2 million compared to €7.8 million in 2021. Revenue for 2022 include SKYTROFA U.S. revenue, and license, clinical supply and services provided to third parties, primarily VISEN Pharmaceuticals. Revenue in 2022 benefited from a full-year contribution of SKYTROFA U.S. revenue of €35.7 million compared to €0.9 million in 2021. Research and development (R&D) costs for 2022 were €379.6 million compared to €295.9 million in 2021. The higher R&D costs in 2022 reflect a one-time reversal of pre-launch inventories in 2021, following the U.S. FDA approval of SKYTROFA in August 2021. In addition, higher R&D costs in 2022 reflect manufacturing of pre-launch inventories for TransCon PTH and an increase in employee and other costs attributable to organizational growth. Selling, general, and administrative (SG&A) expenses for 2022 were €221.2 million compared to €160.2 million in 2021. Higher SG&A expenses were primarily due to an increase in commercial and administrative personnel following the launch of SKYTROFA in the U.S. and preparation for future product launches. Our share of net loss of associate was €17.7 million in 2022, compared to a net gain of €12.0 million in 2021. For 2021, the net profit of associate included a non-cash gain of €42.3 million as a result of a financing round in VISEN. Net finance income was €1.7 million in 2022 compared to a net finance income of €55.8 million in 2021. For the full year 2022, Ascendis Pharma reported a net loss of €583.2 million, or €10.40 per share (basic and diluted) compared to a net loss of €383.6 million, or €7.00 per share (basic and diluted) for the same period in 2021. As of December 31, 2022, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling €742.9 million compared to €789.6 million as of December 31, 2021. As of December 31, 2022, Ascendis Pharma had 57,152,295 ordinary shares outstanding. Conference Call and Webcast Information Ascendis Pharma will host a conference call and webcast today at 4:30 pm Eastern Time (ET) to discuss its full year 2022 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of our website shortly after conclusion of the event for 30 days. About Ascendis Pharma A/SAscendis Pharma is applying its innovative TransCon platform to build a leading, fully integrated, global biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Heidelberg, Berlin and Munich, Germany; Palo Alto and Redwood City, California; and Princeton, New Jersey. Please visit www.ascendispharma.com to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ PDUFA date of April 30, 2023 with respect to the FDA’s Priority Review of TransCon PTH, (ii) the timing of the European MAA decision for TransCon PTH; (iii) the expected launch of TransCon hGH in Germany; (iv) the timing and announcement of Phase 3 data in new adult GHD indication; (v) the ability of Ascendis’ TransCon platform and algorithm for product innovation to address major unmet medical needs with a diverse, growing pipeline of highly differentiated product candidates; (vi) the timing and announcement of top-line results from the foresiGHt Trial and the Phase 1/2 IL-βelieγe Trial; (vii) the timing of completion of patient enrollment in the New InsiGHTS Trial, Phase 2b ApproaCH Trial, dose expansion phase of the Phase 1/2 transcendIT-101 Trial and the Phase 1/2 IL-βelieγe Trial; (viii) the expected commercial launch of TransCon PTH in the U.S. and EU; (ix) the expected submission of an IND for TransCon CNP; (x) Ascendis’ intent to initiate the βelieγe -IT-201 trial of TransCon IL-2β/γ and TLR7/8 combination therapy, (xi) TransCon RBZ’s ability to reduce the intravitreal treatment burden for patients; (xii) Ascendis’ ability to apply its TransCon platform to build a leading, fully integrated global biopharma company, and (xiii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers and distributors to supply Ascendis’ products and product candidates, if approved, for commercial sales in the U.S. and other study drug for clinical studies; unforeseen safety or efficacy results in its oncology and ophthalmology programs, TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to commercialization of Ascendis’ products and product candidates, if approved, in the U.S. and EU, the co-pay program and the further development of Ascendis’ products and product candidates; expenses related to the development and potential commercialization of its oncology and ophthalmology programs, TransCon hGH, TransCon PTH and TransCon CNP or other programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its oncology and ophthalmology programs, TransCon hGH, TransCon PTH and TransCon CNP or other programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on its business from the worldwide COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 2, 2022 and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and Skytrofa® are trademarks owned by the Ascendis Pharma Group. © February 2023 Ascendis Pharma A/S. FINANCIAL TABLES FOLLOW Ascendis Pharma A/S Consolidated Statements of Profit or Loss and Comprehensive Income / (loss) (In EUR'000s, except share and per share data) Year ended December 31, 2022 2021 Revenue51,174 7,778 Cost of sales12,137 3,523 Gross profit39,037 4,255 Research and development costs379,624 295,867 Selling, general and administrative expenses221,227 160,180 Operating profit / (loss)(561,814) (451,792) Share of profit / (loss) of associate(17,697) 12,041 Finance income52,181 59,718 Finance expenses50,487 3,911 Profit / (loss) before tax(577,817) (383,944) Tax on profit / (loss) for the year(5,377) 367 Net profit / (loss) for the year(583,194) (383,577) Attributable to owners of the Company(583,194) (383,577) Basic and diluted earnings / (loss) per share€ (10.40) € (7.00) Number of shares used for calculation (basic and diluted)56,071,793 54,771,763 Net profit / (loss) for the year(583,194) (383,577)Other comprehensive income / (loss) Items that may be reclassified subsequently to profit or loss: Exchange differences on translating foreign operations(327) 3,855 Other comprehensive income / (loss) for the year, net of tax(327) 3,855 Total comprehensive income / (loss) for the year, net of tax(583,521) (379,722) Attributable to owners of the Company(583,521) (379,722) Ascendis Pharma A/S Consolidated Statements of Financial Position (In EUR'000s) December 31, December 31,2022 2021Assets Non-current assets Intangible assets4,828 5,272Property, plant and equipment129,095 126,049Investment in associate22,932 38,345Other receivables1,920 1,808Marketable securities7,492 107,561 166,267 279,035 Current assets Inventories130,673 75,405Trade receivables11,910 2,200Income tax receivable883 893Other receivables12,833 20,093Prepayments31,717 25,231Marketable securities290,688 235,797Cash and cash equivalents444,767 446,267 923,471 805,886 Total assets1,089,738 1,084,921 Equity and liabilities Equity Share capital7,675 7,646Distributable equity255,673 875,989Total equity263,348 883,635 Non-current liabilities Borrowings482,956 97,966Derivative liabilities157,950 -Contract liabilities14,213 2,964 655,119 100,930 Current liabilities Borrowings25,421 6,995Contract liabilities- 2,601Trade payables and accrued expenses101,032 59,417Other liabilities31,989 29,952Income tax payables5,490 198Provisions7,339 1,193 171,271 100,356 Total liabilities826,390 201,286 Total equity and liabilities1,089,738 1,084,921 Investor Contacts:Media Contact:Tim LeeMelinda BakerAscendis PharmaAscendis Pharma+1 (650) 374-6343+1 (650) 709-8875tle@ascendispharma.com media@ascendispharma.com ir@ascendispharma.com Patti Bank ICR Westwicke +1 (415) 513-1284 patti.bank@westwicke.com

Submission of NDA to the NMPA is planned within 2023 at the earliest SHANGHAI, Jan. 6, 2023 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced today that it has completed the double-blind period of PaTHway China Trial, a phase 3 China clinical trial for its innovative investigational new prodrug palopegteriparatide on January 4, 2023, and it would start to carry out analysis of the primary endpoints. Palopegteriparatide is designed to restore parathyroid hormone (PTH [1-34]) to physiological levels over 24 hours in adult patients with hypoparathyroidism (HP). PaTHway China Trial is a randomized, double-blind, placebo-controlled, parallel, multi-center phase 3 trial to assess the potential of palopegteriparatide as a parathyroid hormone replacement therapy. The primary endpoints of the study include evaluating the safety, tolerability, and efficacy of once-daily subcutaneous injections of palopegteriparatide in adults with HP by measuring whether palopegteriparatide -treated patients achieve serum calcium (sCa) levels in the normal range (8.3–10.6 mg/dL) and independence from therapeutic levels of conventional calcium and active vitamin D therapy. VISEN obtained investigational new drug (IND) approval from the National Medical Products Administration (NMPA) on May 31, 2021, allowing it to initiate clinical research of palopegteriparatide in China. On June 16, 2022, VISEN completed patient enrollment for the PaTHway China Trial. HP is the last endocrine deficiency state, where hormone replacement so far has not been established as standard management. It is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH), resulting in low calcium and elevated phosphate levels in the blood. Conventional therapy with calcium supplements and active vitamin D does not effectively address the short-term symptoms, long-term complications, or quality-of-life impacts of HP and can lead to impaired renal function. The once-daily subcutaneous injection of palopegteriparatide is designed to provide sustained exposure within normal physiological range of PTH concentrations. If approved, it is expected to become the first hormone replacement treatment targeting HP in China. Pony LU, CEO and Executive Director of VISEN Pharmaceuticals, said: "The completion of the double-blind period of the phase 3 clinical trial of palopegteriparatide in China means we have moved a step closer towards the success of our research efforts for what we hope will become China's first hormone replacement therapy targeting HP. We will now proceed with the analysis of the primary endpoints of the study and plan to submit a New Drug Application (NDA) to the National Medical Products Administration (NMPA) when all preparation work is completed. We look forward to bringing new treatment options to Chinese HP patients as soon as possible, so that their long-standing suffering could potentially be alleviated sooner." VISEN Pharmaceuticals is developing palopegteriparatide under license from Ascendis Pharma, who received Priority Review from the U.S. Food & Drug Administration (FDA) in 2022 for its New Drug Application (NDA) for this new drug. Ascendis has said that the U.S. FDA has set a target date for completion of its review of its application by April 30, 2023[1]. In addition, Ascendis Pharma also submitted a Marketing Authorization Application (MAA) for palopegteriparatide for adult patients with HP to the European Medicines Agency (EMA)[2]. [1] [2] SOURCE VISEN Pharmaceuticals

“2022年12月2日-4日，由中国医药企业管理协会、中国医药生物技术协会、农工党中央办公厅、杭州城西科创大走廊管理委员会、杭州市投资促进局主办，农工党中央医疗卫生工作委员会、农工党中央生物技术与药学工作委员会、农工党中央青年工作委员会、E药经理人、中国医疗健康产业投资50人论坛承办的主题为“制胜新周期”的第十四届中国医药企业家科学家投资家大会（启思会）在线上成功召开。作为中国医药行业规格最高、影响力最强、规模最大的行业盛会，启思会已连续召开十三届。其秉承赋能中国医药产业创新升级的使命，凝聚企业家、科学家、投资家，旨在打通政府、企业、技术、资本、临床等各要素，构建中国最权威的医药新产品创新发布平台，打造中国医药产业生态的价值链接平台。受疫情影响，为了保障参会人员健康安全，避免不必要的风险，大会由线下改为线上举办，虽然形式有所改变，但会议规格和质量一如既往。大会三天共10场直播，大会直播平台微解药APP统计，线上累计观看人数超20万人次。开幕式上，全国政协副秘书长、农工党中央专职副主席、中国药学会副理事长曲凤宏，杭州市委常委、常务副市长、杭州城西科创大走廊党工委书记柯吉欣，中国医药企业管理协会执行会长吴海东，中国医药生物技术协会驻会副理事长吴朝晖分别为大会致辞。哈佛医学院遗传学教授，美国国家科学院、工程院、艺术与科学院三院院士George Church和中国工程院院士陈志南分别做了题为“原始创新引领生物医药未来”和“后疫情时代的生物技术药物进展”的技术风向标报告。大会还邀请到工信部消费品工业司副司长周健针对“生物医药产业发展趋势”话题进行了分享。除此之外，我们还邀请到中金资本董事长、总裁单俊葆做了“周期更替下的医药投资策略”的投资风向标报告，科睿唯安大中华区管理咨询业务负责人江雪就2022中国医药创新企业100强的榜单进行了发布及解读。在风向标对话中，恒瑞医药董事长孙飘扬与贝达药业董事长丁列明就“经济周期，产业周期，技术周期与企业发展周期交汇形成新风向”这一话题进行了深入的探讨。翰森制药集团执行董事吕爱锋，华盖资本董事长、创始合伙人、H50创始主席许小林，百济神州总裁、首席运营官兼中国区总经理吴晓滨和泰格医药联合创始人、执行董事、总裁曹晓春分别从Big Pharma和Biotech的角度阐述如何穿越新周期。杭州市委常委、常务副市长、杭州城西科创大走廊党工委书记柯吉欣在开幕致辞中提及，杭州市围绕创新研发、临床研究、产业集聚、生态服务等全领域，体系化研究推出了多项政策举措，抢抓产业发展战略机遇，正在加速打造生命健康创新高地。本届大会主办地——杭州城西科创大走廊是浙江省打造的“面向世界、引领未来、服务全国、带动全省”的创新策源地，是举全省、全市之力建设的高能级创新平台。主论坛中，我们邀请到了加科思药业董事长兼首席执行官王印祥，康辰药业董事长王锡娟，维昇药业首席执行官兼执行董事卢安邦、复星国际执行董事、联席CEO，H50轮值主席陈启宇，再鼎医药首席商务官、大中华区总裁梁怡，晶泰科技联合创始人、CEO马健天汇资本业务合伙人邓建良，汇宇制药创始人兼董事长丁兆，纳微科技董事长江必旺，杭州皓阳生物董事长、联合创始人李浩强，海创药业创始人、董事长、总裁陈元伟，君联资本执行董事戚飞，亚盛医药董事长、CEO杨大俊，Oculis全球首席营运官兼中国区总经理丁伟波，天境生物首席科学官王正毅，英矽智能联合首席执行官、首席科学官任峰，驯鹿生物CEO汪文，思拓凡中国总经理俞丽华和济民可信集团副总裁、研发中心首席科学家兼总经理崔海峰分别从医药新周期的脉搏与制胜策略、资本技术与产业整合和中国与全国的合作等话题深入讨论。2022启思会设置多个分论坛，涵盖核酸药物、生产工艺、细胞与基因治疗、IT+BT等研发技术赛道系列论坛，并设置“2022 Think Big 2.0笃行思远双选平台”生物医药创新项目核酸药物与疫苗专场路演、中国医药ESG管理实践论坛、2022年度中国券商十大医药技术研报发布会，同步针对“中国医药创新企业100强榜单”“中国医药创新种子企业100强榜单”“中国医药上市公司竞争力系列评选”“中国医药上市公司ESG竞争力系列评选”和“中国生命科学服务企业品牌100强评选”进行了发布。针对杭州原始创新优势和数字产业优势，设立了“科学家领‘杭’论坛”和“BT+IT杭州生态沙龙”。杭州城西科创大走廊党工委委员管委会副主任祝振伟在科学家领“杭”论坛上表示，创新是这片热土上最鲜明的底色，大走廊始终坚持以创新驱动高质量发展，计划到2025年，基本形成综合性国家科学中心核心承载区功能和国家重要的战略科技力量，已成功创建5家省级实验室、14家国家重点实验室，如良渚实验室、湖畔实验室、西湖实验室和之江实验室，在生命健康领域，有领先地位并基础夯实，特别是基础研究合原创能力。在建2个国家重大科学基础设施，上百家孵化器、众创空间、特色小镇也在孕育着前沿科技和商业创新。杭州市投资促进局副局长盛晓蓉在“BT+IT”杭州生态沙龙上说到，杭州在“BT+IT”融合发展领域具有先天独特优势。基础创新实力领先，集聚了浙江大学、西湖大学等顶尖高校，之江、西湖、良渚等国家和省级重点实验室以及中科院基础医学与肿瘤研究所，原始创新及科研成果转化动力强劲；人才资源丰富，互联网人才流入率全国第一，人工智能人才储备全国第二，人才生态指数全国第四；医疗信息化水平全国领先，6000多家医疗机构的医疗数据实现互联互通，是AI+药物研发企业成长发展的丰厚土壤。新物种企业场景创新数量居全国第三。在杭州见未来，在云里会英雄。听头部共识，探产业底部，制胜新周期。百年变局，以雪为盟，与风同行，煮酒看天下。2022启思会线上回播将会陆续在“微解药APP”上线，敬请关注。相关链接：孙飘扬VS丁列明巅峰思辨：穿越周期，寒冬下要干啥？不干啥？怎么干？启思会风向标：吕爱锋、吴晓滨、曹晓春、许小林，穿越新周期，企业要这样做！2022 “创新100强”解读：头部效应显著，恒瑞中生百济霸榜前3；2010后Biotech占据半壁江山！10年一个新周期？百年MNC穿越周期的秘笈是什么？复星、再鼎、加科思、康辰、维昇共话医药新周期制胜策略支付挑战成发展掣肘，“卖水人”危机已来，资本乏力，同质化竞争下，Biotech原始创新从何而来？国内一级市场创新投资数量已经超过美国！科研院校才是源头创新的活水？礼来放弃国产PD-1海外权益！新药出海之路到底咋走？18家MNC1400条管线布局有何启示？经济周期，产业周期，技术周期与企业发展周期交汇，启思会开启医药风向标对话